Nicotine and Tobacco Message Framing to Change Smoking Behavior in Diverse Groups of Young Adult Smokers

NCT06644664 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2026-03-30

No results posted yet for this study

Summary

This clinical trial evaluates the effect of message framing on smoking behaviors among lesbian, gay, bisexual, transgender, queer (LGBTQ+) young adults who use nicotine and/or tobacco. Tobacco regulation has contributed to a steady decline in tobacco products designed to be smoked (combustible), but there has been an increase in the use of new tobacco products, such as electronic nicotine delivery systems (ENDS). The use of more than one tobacco product (polytobacco) is high in LGBTQ+ populations. Both LGBTQ+ people and people who engage in polytobacco use are less likely to view tobacco as harmful, which may reinforce tobacco use. Message framing includes culturally targeted messages to communicate the absolute risks (AR) and relative risks (RR) of polytobacco use. Using message framing may increase quit rates or change smoking behaviors in LGBTQ+ young adults who use nicotine and/or tobacco products.

Conditions

  • Tobacco-Related Carcinoma

Interventions

BEHAVIORAL

Health Education

Receive control MMS messages

OTHER

Interview

Ancillary studies

BEHAVIORAL

Smoking Cessation Intervention

Receive AR MMS messages

BEHAVIORAL

Smoking Cessation Intervention

Receive RR MMS messages

BEHAVIORAL

Smoking Cessation Intervention

Receive smoking cessation resources

OTHER

Survey Administration

Ancillary studies

OTHER

Text Message-Based Navigation Intervention

Receive check-in text message

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • Ohio State University Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Joanne G Patterson · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-24
Primary Completion
2026-02-02
Completion
2026-02-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06644664 on ClinicalTrials.gov